Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

Blood (2018) 132 (Supplement 1): 163.

https://doi.org/10.1182/blood-2018-163

Published: 2018

Journal Articles

A Pilot Data Analysis of a Metabolomic Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS) Based Study of Patients with Sickle Cell/Beta Thalassemia

Ioannis Papassotiriou, PhD, Christos Poziopoulos, MD, Georgia Avgerinou, MD, Claudia R. Morris, MD, Ersi Voskaridou, MD

Blood (2018) 132 (Supplement 1): 4912.

https://doi.org/10.1182/blood-2018-99-111445

Published: 2018

Journal Articles

Sustainability of Hematological and Clinical Benefits to HU Administration in the Prevention of Sickle-Cell Vaso-Occlusive Crises in Routine Practice

Ersi Voskaridou, MD, Lena Oevermann, MD, Corinne Armari-Alla, MD, Uwe Kordes, MD MRCP, Frédéric Galactéros, MDPhD, Malika Benkerrou, MD, Isabelle Thuret, MD, Dominique Steschenko, MD

Blood (2018) 132 (Supplement 1): 855.

https://doi.org/10.1182/blood-2018-99-116040

Published: 2018

Journal Articles

GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia

Blood (2018) 132 (Supplement 1): 3633.

https://doi.org/10.1182/blood-2018-99-111770

Published: 2018

Journal Articles

Hydroxycarbamide (HU), Sickle Cell Disease and Pregnancy, a Multicentric Retrospective Study

Laure Joseph, MD, Anoosha Habibi, MD, Giovanna Cannas, MD, Stephanie Ngo, MD, Sylvain Le Jeune, MD, Ersi Voskaridou, MD, Elena Foïs, MD, Caroline Makowski, MD, Nathalie Lemonne, MD, Narcisse Elenga, MD, Yves Ville, MD PhD, Alexandra Benachi, MDPhD, Robert Girot, MD, Marina Cavazzana, MD PhD, Jean-Antoine Ribeil, MD PhD

Blood (2016) 128 (22): 1309.

https://doi.org/10.1182/blood.V128.22.1309.1309

Published: 2016

Journal Articles

The Growth Differentiation Factor-15 Levels Are Increased in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia, Correlate with Hepcidin-25/Ferritin Molar Ratio and with Markers of Hemolysis, Endothelial Dysfunction and Angiogenesis

Ioannis Papassotiriou, PhD, Katerina Larrisi, MD, Alexandra Margeli, PhD, Dimitrios Christoulas, Maria Dimopoulou, MD, Vaughn Ostland, PhD, Christos Poziopoulos, Mark Westerman, PhD, Marianna Politou, MD, Ersi Voskaridou, MD, Evangelos Terpos, MD PhD

Blood (2016) 128 (22): 3646.

https://doi.org/10.1182/blood.V128.22.3646.3646

Published: 2016

Journal Articles

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Antonio G. Piga, MD, Immacolata Tartaglione, MD, Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, MD, Paolo Ricchi, MD, Vincenzo Caruso, MD, Antonello Pietrangelo, MD, Xiaosha Zhang, Dawn M. Wilson, Ashley Leneus, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2016) 128 (22): 851.

https://doi.org/10.1182/blood.V128.22.851.851

Published: 2016

Journal Articles

Comparison of the Safety Profile of Sickle Cell Disease Patients Treated with Hydroxycarbamide in Off-Label Versus in-Label Prescriptions in the Escort-HU Non Interventional, Prospective, Observational Open-Label Cohort Study

Ersi Voskaridou, MD, Stephan Lobitz, MD, Uwe Kordes, MD MRCP, Regine Grosse, MD, Valentine Brousse, MD, Malika Benkerrou, MD, Mariane De Montalembert, MD PhD, Jean-Antoine Ribeil, MD PhD, Frederic Galacteros, MD PhD

Blood (2016) 128 (22): 2497.

https://doi.org/10.1182/blood.V128.22.2497.2497

Published: 2016

Journal Articles

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

Antonio Piga, MD, Silverio Perrotta, MD, M.Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, Aldo Filosa, MD, Antonello Pietrangelo, MD, Vincenzo Caruso, MD, Gian Luca Forni, MD, Xiaosha Zhang, Ashley Bellevue, Dawn Wilson, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 752.

https://doi.org/10.1182/blood.V126.23.752.752

Published: 2015

Journal Articles

ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study

Antonio G. Piga, MD, Silverio Perrotta, MD, Angela Melpignano, MD, Caterina Borgna-Pignatti, MD, Ersi Voskaridou, MD, Vincenzo Caruso, MD, Aldo Filosa, MD, Yesim Aydinok, MD, Carrie Condon, Dawn M. Wilson, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2014) 124 (21): 53.

https://doi.org/10.1182/blood.V124.21.53.53

Published: 2014

Journal Articles

Increased Von Willebrand Factor and High Circulating Placental Growth Factor Correlate with Inflammation and Iron Overload in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia

Ersi Voskaridou, MD, Katerina Larrisi, Marianna Politou, Veroniki Komninaka, Filia Apostolakou, Chrysanthi Skevaki, Maria Giannaki, Ioannis Papassotiriou, Evangelos Terpos

Blood (2014) 124 (21): 1392.

https://doi.org/10.1182/blood.V124.21.1392.1392

Published: 2014

Journal Articles

Implementation of a European Cohort to Follow Sickle Cell Children and Adults Treated with Hydroxycarbamide

Mariane De Montalembert, MD, Frédéric Galacteros, Jean Antoine Ribeil, MD PhD, Uwe Kordes, MD MRCP, Jean Benoit Arlet, MD PhD, M Dimopoulou, MD, V Komninaka, MD, Pablo Bartolucci, MD PhD, Anoosha Habibi, Valentine Brousse, MD, Justine Gellen, MD, Stephen Lobitz, MD, Ersi Voskaridou, MD

Blood (2014) 124 (21): 564.

https://doi.org/10.1182/blood.V124.21.564.564

Published: 2014

Journal Articles

Targeted Metabolomic Profiles Are Strongly Correlated With Metabolic Alterations In Patients With Sickle Cell/Beta Thalassemia Disease

Ioannis Papassotiriou, Fottes Panetsos, PhD, Theodora Livadara, MSc, Maria Dimopoulou, MD, Andreas Tzivaras, BSc, Ersi Voskaridou, MD

Blood (2013) 122 (21): 4675.

https://doi.org/10.1182/blood.V122.21.4675.4675

Published: 2013

Journal Articles

Increased Expression of the PRV-1 Gene in Thalassemia Reflects the Rate of the Underlying Erythropoietic Activity.

Katerina Zoi, MSc, Christine Zoi, MSc, Ersi Voskaridou, MD, Evangelos Terpos, MD, Dimitris Loukopoulos, MD

Blood (2005) 106 (11): 2687.

https://doi.org/10.1182/blood.V106.11.2687.2687

Published: 2005

Journal Articles

Osteoporosis in Sickle Cell/β-Thalassemia Is Primarily Caused by an Imbalance at the RANKL/OPG Pathway.

Ersi Voskaridou, MD, PhD, Ioannis Papassotiriou, PhD, Evangelos Premetis, PhD, John Meletis, MD, PhD, Dimitris Loukopoulos, MD, PhD, Evangelos Terpos, MD, PhD

Blood (2005) 106 (11): 3173.

https://doi.org/10.1182/blood.V106.11.3173.3173

Published: 2005

Journal Articles

Zoledronic Acid Is an Effective Treatment for Osteoporosis in Patients with Thalassemia Major: Results of a Randomized, Placebo-Controlled, Trial.

Ersi Voskaridou, MD, PhD, Dimitris Loukopoulos, MD, PhD, Eleni Stoupa, Eugenia Spyropoulou, John Meletis, Evangelos Terpos, MD, PhD

Blood (2005) 106 (11): 3656.

https://doi.org/10.1182/blood.V106.11.3656.3656

Published: 2005

NARROW

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

A Pilot Data Analysis of a Metabolomic Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS) Based Study of Patients with Sickle Cell/Beta Thalassemia

Sustainability of Hematological and Clinical Benefits to HU Administration in the Prevention of Sickle-Cell Vaso-Occlusive Crises in Routine Practice

GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia

Hydroxycarbamide (HU), Sickle Cell Disease and Pregnancy, a Multicentric Retrospective Study

The Growth Differentiation Factor-15 Levels Are Increased in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia, Correlate with Hepcidin-25/Ferritin Molar Ratio and with Markers of Hemolysis, Endothelial Dysfunction and Angiogenesis

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Comparison of the Safety Profile of Sickle Cell Disease Patients Treated with Hydroxycarbamide in Off-Label Versus in-Label Prescriptions in the Escort-HU Non Interventional, Prospective, Observational Open-Label Cohort Study

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study

Increased Von Willebrand Factor and High Circulating Placental Growth Factor Correlate with Inflammation and Iron Overload in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia

Implementation of a European Cohort to Follow Sickle Cell Children and Adults Treated with Hydroxycarbamide

Targeted Metabolomic Profiles Are Strongly Correlated With Metabolic Alterations In Patients With Sickle Cell/Beta Thalassemia Disease

Increased Expression of the PRV-1 Gene in Thalassemia Reflects the Rate of the Underlying Erythropoietic Activity.

Osteoporosis in Sickle Cell/β-Thalassemia Is Primarily Caused by an Imbalance at the RANKL/OPG Pathway.

Zoledronic Acid Is an Effective Treatment for Osteoporosis in Patients with Thalassemia Major: Results of a Randomized, Placebo-Controlled, Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only